All Resolutions Approved, Including the Sale to Charme Capital Partners

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 04, 2024 — Centogene N.V. (OTC: CNTGF), a leading life sciences company specializing in data-driven solutions for rare and neurodegenerative diseases, today announced the results of its Extraordinary General Meeting. Shareholders approved all proposed resolutions, including the previously announced sale of Centogene GmbH to Charme Capital Partners Limited, a major pan-European private equity firm.

The Extraordinary General Meeting of CENTOGENE had 57.16% of the Company’s issued share capital represented.

About CENTOGENE

CENTOGENE’s mission is to deliver data-driven solutions that transform the lives of patients, physicians, and pharmaceutical companies working on rare and neurodegenerative diseases. We integrate multiomic technologies with the CENTOGENE Biodatabank, offering comprehensive analysis to advance precision medicine. Our approach enables fast, accurate diagnoses for patients, improves physician understanding of diseases, and accelerates and reduces the risk in pharmaceutical drug discovery, development, and commercialization.

Founded in 2006, CENTOGENE has provided rapid, reliable diagnoses, building a network of roughly 30,000 active physicians. Our ISO, CAP, and CLIA certified multiomic reference laboratories in Germany utilize Phenomic, Genomic, Transcriptomic, Epigenomic, Proteomic, and Metabolomic datasets. This data is housed in our CENTOGENE Biodatabank, encompassing over 850,000 patients from more than 120 diverse countries, over 70% of whom are non-European. The CENTOGENE Biodatabank has contributed to over 300 peer-reviewed publications.

By translating our data and expertise into actionable insights, we’ve supported over 50 collaborations with pharmaceutical partners. Together, we accelerate and de-risk drug discovery, development, and commercialization across target and drug screening, clinical development, market access and expansion. We also offer CENTOGENE Biodata Licenses and Insight Reports, working towards a world free from rare and neurodegenerative diseases.

To learn more about our offerings, pipeline, and patient-centric approach, please visit and follow us on .

Forward-Looking Statements

This press release includes “forward-looking statements” as defined by U.S. federal securities laws. Statements that are not strictly historical are forward-looking. Words like “anticipate,” “believe,” “continue,” “expect,” “estimate,” “intend,” “project,” “plan,” “is designed to,” “potential,” “predict,” “objective,” and similar expressions, along with future or conditional verbs such as “will,” “would,” “should,” “could,” “might,” “can,” and “may,” or their negatives, typically indicate forward-looking statements. These may include statements on the anticipated timing of the transaction’s closing, the ability to complete the transaction, sufficient short-term loan financing, funds available for stockholder distribution (if any), plans for dissolution and liquidation, and suspension of U.S. securities law reporting obligations, and underlying assumptions. Such statements involve known and unknown risks, uncertainties, and other factors that could significantly alter CENTOGENE’s actual results from those expressed or implied. These risks include: (i) the possibility of the transaction not being completed, (ii) uncertainties regarding the timing of completion and potential failure to meet closing conditions, (iii) unexpected costs, liabilities, or delays, (iv) effects of the announcement, pendency, or completion on personnel, customer relationships, and operations, (v) negative impacts due to uncertainty and management distraction, (vi) outcomes of legal proceedings, (vii) adverse economic, business, and competitive factors, (viii) events that could terminate the agreement and transaction, (ix) restrictions impacting business opportunities during the transaction, (x) negative economic and geopolitical conditions, (xi) legislative, regulatory, and policy changes, (xii) ability to streamline cash usage, (xiii) compliance with financial instrument covenants, (xiv) need for additional financing, and (xv) ability to remain a going concern. For further details on risks and uncertainties, including those related to CENTOGENE’s business, see CENTOGENE’s Form 20-F (filed May 15, 2024, with the Securities and Exchange Commission (SEC)) and subsequent SEC filings. Forward-looking statements apply only as of today’s date; CENTOGENE disclaims any obligation to update them.

CONTACT

CENTOGENE
Melissa Hall
Corporate Communications

Lennart Streibel
Investor Relations

“`